ACTRN12612000249853
Completed
Phase 2
In Dermatologist or Allergist diagnosed eczema, does use of multi-transient receptor potential modifying compound (MTRPMC) formulation plus placebo compared with no MTRPMC formulation plus placebo improve PO SCORAD
Peter Smith0 sites20 target enrollmentFebruary 29, 2012
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Peter Smith
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Dermatologist or Allergist diagnosed eczema severity moderate\-severe
- •Significant impairment of quality of life
- •Need for frequent moisturising and topical steroids
- •Must have indicated a willingness to enter the study
- •Must have read and fully understood a study information form
- •Must have had the opportunity to ask any questions prior to enrolment
- •Must have signed study consent form
Exclusion Criteria
- •Pregnant or likely to become pregnant
- •People whose primary language is other than English (LOTE)
- •People with a cognitive impairment, an intellectual disability or a mental illness
- •Children and/or young people (ie. \<18 years)
- •Any history of reaction or intolerance to MTRPMC formulation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A Pilot Study of Topical Honey for the Treatment of EczemaEczemaSkin - Dermatological conditionsACTRN12612000561886Medical Research Institute of New Zealand15
Withdrawn
Phase 3
Beyond conventional treatment of Atopic eczema in infants: Management By specific prObiOtic strains. A double blind placebo-controlled trial.allergyatopic dermatitiseczema1000170810014982NL-OMON34286Sint Antonius Ziekenhuis120
Completed
Not Applicable
A Randomised Placebo-Controlled Trial to compare Dilute Bleach Baths with Water treatment of Children with Eczema.EczemaBacterial Colonisation of the SkinSkin - Dermatological conditionsInfection - Studies of infection and infectious agentsACTRN12611000260921Dr Michael Herd64
Not yet recruiting
Not Applicable
A Study On Drugs Used In Eczema Patients In a Tertiary Care HospitalHealth Condition 1: L209- Atopic dermatitis, unspecifiedCTRI/2020/12/029854I
Suspended
Phase 2
Combined Subcutaneous immunotherapy VALERGEN-DP and VALERGEN-BT-Asthma-Adults-Phase IIRPCEC00000127ational Center of Bioproducts (BIOCEN)120